The benefit was seen in an all-comers population, according to the presenters at ESMO Congress 2019.
Researchers sought to determine if practicing Kegel exercises, a common pelvic-floor exercise, could prevent urinary and fecal incontinence in patients with prostate cancer.
This study provided evidence suggesting that advanced NSCLC characterized by a genomic alterations in both STK11 and KRAS may not respond well to immunotherapy.
In TAILORx, 84% of patients with a high recurrence score were treated with chemotherapy containing a taxane and/or an anthracycline prior to endocrine therapy.
“Despite a lack of head-to-head trials, there is a perception that irAE profiles arecomparable between agents,” the abstract authors wrote.
More than 15,000 distinct irAEs were found for 13,030 patients.
Liquid biopsy can be used to detect a complex type of driver mutation, called ALK, in patients with NSCLC.
While pembrolizumab was not superior to chemotherapy, survival times were similar, suggesting immunotherapy might offer an alternative to chemotherapy.
Results of the YoungPearl study revealed that patient-reported QoL scores were high for palbociclib plus endocrine therapy.
Results of MONARCH-2 showed a statistically significant and clinically meaningful improvement in overall survival with abemaciclib plus fulvestrant.
At 3-year follow-up, the mean LVEF was over 60% in both study arms.
One finding was a drop in concordance rate for clonal alterations when NGS was performed on tumor tissue and ctDNA samples collected following treatment initiation.
Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence following nephrectomy.
“In my opinion, these data are practice changing,” said lead study author Solange Peters.
The precision of the targeted methylation sequencing assay for localizing the cancer tissue of origin was reported to be 89%.
Pembrolizumab monotherapy does not improve overall survival (OS) compared with single-agent chemotherapy among women with metastatic triple negative breast cancer (mTNBC).
The addition of bevacizumab to temozolomide-based chemotherapy was also associated with higher rates of grade 3 or higher thrombocytopenia and anemia.
Interestingly, concordance for estimates of TMB between NGS panels was higher for tumor specimens with a low compared with a high PD-L1 expression level.
Nearly 11% of patients in the study who underwent immune checkpoint inhibition for NSCLC experienced HPD.
Nivolumab monotherapy for advanced NSCLC was associated with lower overall survival rates in real-world settings than those seen in clinical trial settings.